Cargando…

Impact of NKG2D Signaling on Natural Killer and T‐Cell Function in Cerebral Ischemia

BACKGROUND: Typically defined as a thromboinflammatory disease, ischemic stroke features early and delayed inflammatory responses, which determine the extent of ischemia‐related brain damage. T and natural killer cells have been implicated in neuronal cytotoxicity and inflammation, but the precise m...

Descripción completa

Detalles Bibliográficos
Autores principales:	David, Christina, Ruck, Tobias, Rolfes, Leoni, Mencl, Stine, Kraft, Peter, Schuhmann, Michael K., Schroeter, Christina B., Jansen, Robin, Langhauser, Friederike, Mausberg, Anne K., Fender, Anke C., Meuth, Sven G., Kleinschnitz, Christoph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10356034/ https://www.ncbi.nlm.nih.gov/pubmed/37301761 http://dx.doi.org/10.1161/JAHA.122.029529

Ejemplares similares

Natural Killer Cells Are Present in Rag1(−/−) Mice and Promote Tissue Damage During the Acute Phase of Ischemic Stroke
por: Rolfes, Leoni, et al.
Publicado: (2021)

B cells do not have a major pathophysiologic role in acute ischemic stroke in mice
por: Schuhmann, Michael K., et al.
Publicado: (2017)

Platelet depletion does not alter long-term functional outcome after cerebral ischaemia in mice
por: Steubing, Rebecca D., et al.
Publicado: (2022)

C1-Inhibitor protects from focal brain trauma in a cortical cryolesion mice model by reducing thrombo-inflammation
por: Albert-Weissenberger, Christiane, et al.
Publicado: (2014)

The NKG2D – IL-15 signaling pathway contributes to T-cell mediated pathology in inflammatory myopathies
por: Ruck, Tobias, et al.
Publicado: (2015)

Effectiveness and safety of cladribine in MS: Real-world experience from two tertiary centres
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Dimethyl Fumarate Attenuates Lymphocyte Infiltration and Reduces Infarct Size in Experimental Stroke
por: Schuhmann, Michael K., et al.
Publicado: (2023)

Merits and culprits of immunotherapies for neurological diseases in times of COVID-19
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Risiken und Chancen von Immuntherapien in Zeiten der Coronavirus-2019-Pandemie
por: Pawlitzki, Marc, et al.
Publicado: (2020)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Comparing Plasma Exchange to Escalated Methyl Prednisolone in Refractory Multiple Sclerosis Relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2019)

Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Hypercholesterolemia induced cerebral small vessel disease
por: Kraft, Peter, et al.
Publicado: (2017)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Fingolimod (FTY720-P) Does Not Stabilize the Blood–Brain Barrier under Inflammatory Conditions in an in Vitro Model
por: Schuhmann, Michael K., et al.
Publicado: (2015)

Therapeutic Apheresis in Acute Relapsing Multiple Sclerosis: Current Evidence and Unmet Needs—A Systematic Review
por: Rolfes, Leoni, et al.
Publicado: (2019)

Enjoy Carefully: The Multifaceted Role of Vitamin E in Neuro-Nutrition
por: Regner-Nelke, Liesa, et al.
Publicado: (2021)

Generation of a Model to Predict Differentiation and Migration of Lymphocyte Subsets under Homeostatic and CNS Autoinflammatory Conditions
por: Gross, Catharina C., et al.
Publicado: (2020)

Deciphering the biology of NKG2C+ natural killer cells
por: Rölle, Alexander
Publicado: (2015)

Glatiramer acetate does not protect from acute ischemic stroke in mice
por: Kraft, Peter, et al.
Publicado: (2014)

Crosstalk of Microorganisms and Immune Responses in Autoimmune Neuroinflammation: A Focus on Regulatory T Cells
por: Schroeter, Christina B., et al.
Publicado: (2021)

Driving time-based identification of gaps in specialised care coverage: An example of neuroinflammatory diseases in Germany
por: Masanneck, Lars, et al.
Publicado: (2023)

Introducing electronic monitoring of disease activity in patients with chronic inflammatory demyelinating polyneuropathy (EMDA CIDP): trial protocol of a proof of concept study
por: Masanneck, Lars, et al.
Publicado: (2023)

Current Biomarker Strategies in Autoimmune Neuromuscular Diseases
por: Oeztuerk, Menekse, et al.
Publicado: (2023)

A case of idiopathic multicentric Castleman disease in an alemtuzumab-treated patient with MS
por: Rolfes, Leoni, et al.
Publicado: (2019)

CD4(+)NKG2D(+) T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation
por: Ruck, Tobias, et al.
Publicado: (2013)

One Brain—All Cells: A Comprehensive Protocol to Isolate All Principal CNS-Resident Cell Types from Brain and Spinal Cord of Adult Healthy and EAE Mice
por: Schroeter, Christina B., et al.
Publicado: (2021)

Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
por: Korsen, Melanie, et al.
Publicado: (2022)

Role of the kallikrein–kinin system in traumatic brain injury
por: Albert-Weissenberger, Christiane, et al.
Publicado: (2014)

The Innate Immune Response Characterizes Posterior Reversible Encephalopathy Syndrome
por: Nelke, Christopher, et al.
Publicado: (2021)

CD28 superagonist-mediated boost of regulatory T cells increases thrombo-inflammation and ischemic neurodegeneration during the acute phase of experimental stroke
por: Schuhmann, Michael K, et al.
Publicado: (2015)

ERK1/2 Activity Is Critical for the Outcome of Ischemic Stroke
por: Schanbacher, Constanze, et al.
Publicado: (2022)

Correction: CD4(+)NKG2D(+) T Cells Exhibit Enhanced Migratory and Encephalitogenic Properties in Neuroinflammation
por: Ruck, Tobias, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cd5mc5mm2t1bob64mvr1cb0f8m